TY  - JOUR
AU  - Jiménez-Reinoso, Anaïs
AU  - Tirado, Néstor
AU  - Martinez-Moreno, Alba
AU  - Díaz, Víctor M
AU  - García-Peydró, Marina
AU  - Hangiu, Oana
AU  - Díez-Alonso, Laura
AU  - Albitre, Ángela
AU  - Penela, Petronila
AU  - Toribio, Maria L
AU  - Menéndez, Pablo
AU  - Álvarez-Vallina, Luis
AU  - Sánchez Martínez, Diego
AU  - valli
PY  - 2022
DO  - 10.1136/jitc-2022-005333
UR  - http://hdl.handle.net/20.500.12105/18958
AB  - BACKGROUNDThe dismal clinical outcome of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) highlights the need for innovative targeted therapies. Although chimeric antigen receptor (CAR)-engineered T cells have revolutionized the...
LA  - eng
PB  - BMJ Publishing Group
KW  - T-Lymphocytes
KW  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
KW  - Humans
KW  - Immunotherapy, Adoptive
KW  - Antibodies
KW  - Recurrence
TI  - Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
TY  - journal article
ER  -